Purpose Pemetrexed is a recognized active agent for the second-line treatment for
advanced non-small cell lung cancer (NSCLC). This study was undertaken to evaluate the …

Background and objective Pemetrexed is a standard second-line therapy in advanced non-
small cell lung cancer (NSCLC). Currently, cytotoxic treatments beyond second-line therapy …

Objective Pemetrexed has been approved for second-line treatment in non-small cell lung
cancer (NSCLC). However, the role of third-line pemetrexed therapy in NSCLC has not yet …

BACKGROUND: We sought to identify the relationship between response to previous
systemic treatment and the efficacy of subsequent pemetrexed therapy in advanced non …

Abstract On September 26, 2008, the US Food and Drug Administration approved
pemetrexed injection (Alimta® Injection; Eli Lilly and Company, Indianapolis, IN) for use in …

Methods Patients with histologically or cytologically confirmed NSCLC were evaluated from
April 2007 to March 2009. The patients had relapsed or progressed after prior chemotherapy …

Background Pemetrexed is widely used for the treatment of advanced non-squamous non-
small-cell lung cancer (NSCLC). However, factors that can predict the benefits of …

Background: Pemetrexed is an effective salvage agent in NSCLC. Our aim was to evaluate
the efficacy of pemetrexed in NSCLC patients who had failed previous platinum-based …

Several drugs have been approved for the treatment of patients affected by advanced non-
small cell lung cancer (NSCLC) in progression after first line chemotherapy: Docetaxel …

Importance of the field: Current therapeutic options for advanced non-small-cell lung cancer
(NSCLC) yield relatively modest improvements in survival leading to an ongoing search for …